GABA-AT Inhibitor OV329 Shows Safety, Preliminary Target Engagement in Phase 1 Study Marco Meglio

Published Date: 10 Dec 2025

Ovid Therapeutics' OV329 shows promise as a safe, effective GABA-AT inhibitor for treating drug-resistant seizures, with strong phase 1 trial results.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

PET-CT finds further-reaching metastases in patients with locally advanced breast cancer.

2.

Pancreatic cancer RNA vaccine shows durable T cell immunity

3.

Patients value communication skills from cancer surgeons across six key areas, according to research

4.

Why Did Rare Cancer Shrink on Its Own?

5.

Two medications might work better for breast cancers that are resistant to one.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot